Trails Edge Capital Partners LP Buys New Stake in 4D Molecular Therapeutics, Inc. $FDMT

Key Points

• Trails Edge Capital Partners purchased 2,227,917 shares of 4D Molecular Therapeutics, giving it approximately 4.26% of the company and making FDMT about 4.7% of the firm’s portfolio. Institutional investors collectively own 99.27% of the stock.
• Analyst sentiment is broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $29.62, despite one sell rating.
• FDMT was trading at $15.72, near its 52-week high, while its latest quarterly loss of $1.04 per share slightly missed estimates; revenue of $3.78 million exceeded expectations.

Trails Edge Capital Partners LP purchased a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,227,917 shares of the company's stock, valued at approximately $29,631,296,000. 4D Molecular Therapeutics makes up about 4.7% of Trails Edge Capital Partners LP's holdings, making the stock its 5th largest position. Trails Edge Capital Partners LP owned about 4.26% of 4D Molecular Therapeutics as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Legal & General Group Plc purchased a new position in shares of 4D Molecular Therapeutics in the 2nd quarter valued at about $59,000. Wexford Capital LP purchased a new stake in 4D Molecular Therapeutics during the third quarter worth approximately $41,000. Daiwa Securities Group Inc. boosted its holdings in 4D Molecular Therapeutics by 3,362.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company's stock valued at $48,000 after purchasing an additional 6,186 shares in the last quarter. Susquehanna Portfolio Strategies LLC acquired a new position in 4D Molecular Therapeutics in the fourth quarter valued at approximately $77,000. Finally, Martingale Asset Management L P increased its stake in 4D Molecular Therapeutics by 12.4% in the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company's stock valued at $88,000 after purchasing an additional 1,303 shares during the last quarter. 99.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Chardan Capital raised shares of 4D Molecular Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. B. Riley Financial restated a "buy" rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. The Goldman Sachs Group reaffirmed a "buy" rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright reissued a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $29.62.

Insider Buying and Selling at 4D Molecular Therapeutics

In other news, insider Scott Bizily sold 9,810 shares of the company's stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the sale, the insider directly owned 8,617 shares of the company's stock, valued at approximately $103,404. This represents a 53.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Kirn sold 12,415 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $10.05, for a total transaction of $124,770.75. Following the sale, the insider owned 871,737 shares of the company's stock, valued at $8,760,956.85. This trade represents a 1.40% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 200,496 shares of company stock valued at $2,240,244. 7.90% of the stock is owned by insiders.

4D Molecular Therapeutics Trading Up 2.1%

NASDAQ:FDMT opened at $15.72 on Wednesday. The stock's 50 day moving average price is $11.88 and its 200 day moving average price is $10.21. The company has a market capitalization of $868.37 million, a PE ratio of -5.98 and a beta of 2.73. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics, Inc. has a 52-week low of $5.97 and a 52-week high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The firm had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. On average, research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

Want to see what other hedge funds are holding FDMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source